MedTrace Logo

Cardiovascular Risk in T2DM With MAFLD: A Cohort Study

NCT07706010 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2026-07-15

No results posted yet for this study

Summary

This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes in patients with T2DM, after excluding the confounding effects of traditional cardiovascular risk factors. Its technical value lies in utilizing prospective follow-up data combined with a multivariable competing risks model to develop and validate a cardiovascular risk prediction and early warning system tailored for Chinese populations with T2DM complicated by MASLD. Clinically, the findings will provide interdisciplinary evidence-based support for endocrinology and cardiology, helping clinicians identify high-risk individuals and prevent cardiovascular events through early intervention targeting hepatic metabolic disorders. This has significant implications for reducing overall mortality among diabetic patients in China and alleviating the public health burden.

Conditions

  • Type 2 Diabetes (T2DM)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Sponsors & Collaborators

  • The Affiliated Hospital of Hangzhou Normal University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-12
Primary Completion
2028-05-29
Completion
2031-05-29

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706010 on ClinicalTrials.gov